Trial Profile
Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Cholic acid (Primary)
- Indications Inborn error metabolic disorders
- Focus Therapeutic Use
- Sponsors Asklepion Pharmaceuticals; Mirum Pharmaceuticals
- 17 Mar 2015 According to Asklepion Pharmaceuticals media release, US FDA has approved cholic acid [CHOLBAM] as a once daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects
- 03 Feb 2015 New trial record